

**THIS PAGE IS INSERTED BY OIPE SCANNING
AND IS NOT PART OF THE OFFICIAL RECORD**

Best Available Images

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

BLACK BORDERS

TEXT CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT

BLURRY OR ILLEGIBLE TEXT


SKEWED/SLANTED IMAGES

COLORED PHOTOS HAVE BEEN RENDERED INTO BLACK AND WHITE

VERY DARK BLACK AND WHITE PHOTOS

UNDECIPHERABLE GRAY SCALE DOCUMENTS

**IMAGES ARE THE BEST AVAILABLE
COPY. AS RESCANNING *WILL NOT*
CORRECT IMAGES, PLEASE DO NOT
REPORT THE IMAGES TO THE
PROBLEM IMAGE BOX.**



Attorney Docket No. 54269.8002.US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Group Art Unit: Thai-An N. Ton
Kangsheng Wang)	Examiner: 1632
Serial No. 09/781,046)	
Filed: February 8, 2001)	
For: A Method and System for Introducing a Gene)	
into a Human Stem Cell)	
_____)	

AFFIDAVIT OF KANGSHENG WANG

PURSUANT TO 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

I, Kangsheng Wang, hereby declare, subject to penalty of perjury, as follows:

1. I am currently President and Chief Executive Officer of BioAgri Corporation ; I have been involved in the research of molecular biology for over 22 years; I obtained a Ph.D. degree in Biology from the California Institute of Technology in 1991; I worked at Chiron Corporation as Research Associate for 3 years and Scientist for 7 years; and I have published about 12 research papers in well known scientific journals.

2. I have reviewed the United States Patent Application No. 09/781,046 entitled "A Method and System for Introducing A Gene Into A Human Stem Cell" filed February 8, 2001 (the '046 Application) and the United States Patent Application No. 09/573,861 entitled "A New Vector

For Genetically Modifying Non-Human Animals” filed March 28, 2000 (the ‘861 Application), wherein the ‘046 Application is a continuation-in-part application of the ‘861 Application.

3. I am the sole inventor of the ‘046 and ‘861 Applications.

4. I have read and understood the Office Action dated April 26, 2002 and the Final Office Action dated February 11, 2003, regarding the ‘046 Application. The Final Office Action maintains the rejections of claims 22 – 26 of the ‘046 Application under 35 U.S.C.112, first paragraph, since the Final Office Action asserts that "in general antibodies directed to sperm would be expected to inhibit fertilization" and "it would have required undue experimentation for one skilled in the art to expect that the sperm-specific antibodies of the instant invention would retain the ability to fertilize an oocyte."

5. I have made more than one antibodies that bind to a sperm, retain the ability of the sperm bound with the antibody to fertilize an oocyte, and carry DNA into the oocyte from which a transgenic animal developed, through the use of the same method as disclosed in the ‘046 and ‘861 Applications.

6. I include a copy of pertinent pages of my original laboratory records dated from March 15, 1999 to February 8, 2001, as shown in Appendix A submitted herein.

Page 4 of the Appendix A demonstrates that mouse sperm cells were collected and used to immunize mice to produce antibodies against the sperm cells. This procedure is identical to what was described in Example I of the ‘861 Application (p. 10, ll. 20-21, the ‘861 Application).

Pages 6 to 10 of the Appendix A show that a number of hybridoma supernatants generated from the mice immunized by mice sperm cells do not prohibit sperms from fertilizing oocytes. In particular, hybridoma supernatants were incubated with sperm cells first and the mixture was

incubated with oocytes for *in vitro* fertilization (Page 6). It was observed that hybridoma supernatants nos. 1B3, 1F5, 2D4, 2E8, 3C7, 4E7 did not inhibit fertilization. In a re-testing process, sub-supernatant 1A8 from 1B3, sub-supernatant 1F3 from 2D4, sub-supernatant 2C5 from 3C7, sub-supernatant 2G5 from 2E8, sub-supernatant 1F11 from 4E7, and sub-supernatant 1D8 from 1F5 all retained fertilization (Page 9 of the Appendix A).

Pages 12 to 20 of the Appendix A illustrate that the hybridoma supernatants that retained fertilization contained antibodies that bind to sperm cells. As shown in page 10, hybridoma supernatants 1B3(1A8), 2D4 (1F3), 3C7(2C5), 2E8(2G5), 4E7(1F11), 1F5(1D8) were marked as mouse antibody A, B, C, D, E and F respectively. The flow cytometry method as disclosed in Example I of the '861 Application (p. 10, l. 21 to p. 11, ll. 8, the '861 Application) was conducted to determine whether the antibodies bind to sperm cells. It was observed that mouse antibody A which is mAbA bound to mouse sperm cells (Page 17), so did mouse antibody B which is mAbB (Page 18), mouse antibody C which is mAbC (Page 19), and mouse antibody D which is mAbD (Page 20).

Pages 22 to 23 further illustrate that mAbC and mAbD both have shown to carry transgene DNA into an oocyte from which a transgenic mouse develops. The procedures to generate a transgenic mouse are identical to Example IV of the '861 Application (p. 15, l. 1 to p. 16, l. 6 of the '861 Application). The Southern blot analysis was performed to confirm whether the transgene DNA was integrated into the genome of the transgenic mouse (Example IV of the '861 Application). As shown in page 22 of the Appendix A, the transgenic mice generated using mAbC contained the transgene in their genome. The transgenic mice generated using mAbD also contained the transgene in their genome (page 23 of the Appendix A).


In light of the foregoing, it is concluded that a number of antibodies, including 1B3(1A8),

2D4 (1F3), 3C7(2C5), 2E8(2G5), 4E7(1F11), and 1F5(1D8), have been made according to the method disclosed in the '861 Application, and have binding affinity to sperm cells and the sperm cells bound with the antibodies retain the ability to fertilize oocytes. In addition, more than one antibody (mAbC and mAbD) has demonstrated that sperm cells bound with the antibody are able to carry transgene DNA and fertilize an oocyte from which a transgenic animal develops and contains the transgene.

7. I note that the mAbC in the '046 Application is identical to the mAbC in the '861 Application and is made by the method as disclosed in the '861 Application.

8. I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and, further, that these statements are made with knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of United States Applications No. 09/781,046 and United States Patent Application No. 09/573,861, any patent issuing thereon, or any patent to which this verified statement is directed.

Executed and signed on Oct 13, 2003, at City of Industry, California,


Kangsheng Wang

Linker Based Sperm-Mediated Gene Transfer Technology

1. Over-Immunization of Balb/C Mice with Mouse Sperm Cells
2. Screen Hybridomas Which Does Not Prevent Sperm Fertilization by In Vitro Fertilization
3. Flow Cytometry Analysis of mAbs Bound to Mouse Sperm Cells
4. Generation of Transgenic Mice from Two Different Linkers mAb C and mAb D

Over-Immunization of Balb/C Mice with Mouse Sperm Cells

Work continued from Page

1. Immunize 3 Balb/c mice with 2×10^6 ~~B6D2F1~~ ^{B6D2F1} and FVB male sperm
overimmune 8 time (twice/month) (2 for FVB sperm)
1 for B6D2F1 sperm)

a. dissect epididymis of 12-15 weeks olds male, squeeze the sperm
out from and let sperm in Modified Tyrode's medium without
BSA.

b. wash sperm with MTM three time ^{count Number} and immunize mix with 200ul
TDM.

c. Immunize ^{5 weeks old} Balb/c female (twice/month)

SIGNATURE

DATE
3/15/99

DISCLOSED TO AND UNDERSTOOD BY

DATE

WITNESS

DATE
10-1-99
B 100 P ©

Screen Hybridomas Which Does Not Prevent Fertilization by In Vitro Fertilization

(screening assay shows that a number of hybridomas supernatants does not inhibit sperm cells bound with antibodies in the supernatant to fertilize oocytes.)

Work continued from Page

Test in vitro fertilization efficiency and blocking by mAb (hybridoma supernatant)

1. Set 20 egg/assay for IVF study, and

2. inject with 5 I.U. PMS (Sigma) ~~to~~ in 8 p.m. (day 1)50 B6D₃F₁ female with 8 weeks old3. 48 hours later, each mouse ~~was~~ injected with 5 I.U. hCG (day 3)4. On day 4 at 7:30 a.m., ~~the~~ sacrifice the female mice and collect egg from with cumulus cell from swollen ampulla in MTM medium.5. ~~Add~~ Distribute each one clump of cumulus cell with egg to ^(average 20 cl egg) each ~~in~~ 48 of 48 well dish in 200ul MTM medium6. Add 20ul of supernatant of hybridoma to each well and incubate with 5×10^4 sperm in 30ul MTM medium for 30 min7. add sperm mix to (5) _{in (6)} and incubate in 37°C for 4 hr for in vitro fertilization8. ~~collect~~ collect and transfer ^{fertilized} eggs to CZB medium and incubate at 37°C for 20-22 hrs in ~~96 well~~9. observe the fertilization efficiency (++) ^{No} block fertilization ~~very much~~ of sup. of hybridoma
(++) block ~~ok~~ some
(+) block was a little
blank blocked

Work continued to Page

SCIENTIFIC BINDERY PRODUCTIONS CHICAGO 60605 MADE IN USA

SIGNATURE

Ken Wang

DATE

7/10/99

DISCLOSED TO AND UNDERSTOOD BY

DATE

WITNESS

[Signature]

DATE

10-1-99

Supernatant from
hybridoma from mouse
immunized with
FVB and B6D₃F₁ mouse
sperm

Group 3 (+)

1 A 4
1 B 5
1 F 6
2 A 10
2 B 2
2 E 3
2 F 4
3 B 7
3 D 4
4 C 8
4 C 9

Group 2 (++)

1 B 8
1 C 4
1 G 10
2 B 1
2 C 8
2 E 2
2 E 4
3 A 7
3 A 10
3 B 8
3 G 2



Group 1 (+++ or +++)

1 B 3
1 F 5
2 D 4
2 E 8
3 C 7
4 E 7

1	2	3	4	5	6	7	8	9	10	11	12
A1	A2	A3	A4	A5	A6	A7	A8	A9	A10	A11	A12
B1	B2	B3	B4	B5	B6	B7	B8	B9	B10	B11	B12
C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11	C12
D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11	D12
E1	E2	E3	E4	E5	E6	E7	E8	E9	E10	E11	E12
F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12
G1	G2	G3	G4	G5	G6	G7	G8	G9	G10	G11	G12
H1	H2	H3	H4	H5	H6	H7	H8	H9	H10	H11	H12
I1	I2	I3	I4	I5	I6	I7	I8	I9	I10	I11	I12
J1	J2	J3	J4	J5	J6	J7	J8	J9	J10	J11	J12

1	2	3	4	5	6	7	8	9	10	11	12
A1	A2	A3	A4	A5	A6	A7	A8	A9	A10	A11	A12
B1	B2	B3	B4	B5	B6	B7	B8	B9	B10	B11	B12
C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11	C12
D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11	D12
E1	E2	E3	E4	E5	E6	E7	E8	E9	E10	E11	E12
F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12
G1	G2	G3	G4	G5	G6	G7	G8	G9	G10	G11	G12
H1	H2	H3	H4	H5	H6	H7	H8	H9	H10	H11	H12
I1	I2	I3	I4	I5	I6	I7	I8	I9	I10	I11	I12
J1	J2	J3	J4	J5	J6	J7	J8	J9	J10	J11	J12

group 1 (+++ or +++)	group 2 (++)	group 3 (+)	Retest
1 A 7	1 A 5	1 C 1	Two-time ① show (+++ or +++) two-time twice ② show ++ once ++ once
1 C 5	2 A 1	0 C 6	
1 C 12	2 A 2	1 D 9	
1 F 3	3 A 5	2 A 11	
1 H 12	3 C 6	2 B 4	2 B 1
2 B 10	3 C 8	2 B 7	2 C 8
2 D 5	3 D 7	2 B 7	3 A 10
2 D 8	3 E 9	3 C 4	3 G 2
2 E 10	3 G 8	4 E 12	③ show ++ twice
3 A 6	4 E 11	4 G 4	1 G 10
4 C 10			2 E 2
			2 E 4
			4 A 8
			4 B 4
			4 E 3



3C7

Δ_{2C5} (tt) twice

108 (++) once (+) once

2C6 (H) once (T) once

2D10 (++) once (+) once

2E8

Δ 245. (++) twice

248 (11) twice

1c10 (tt) twice

1c10 (tt) twice

1c10 (tt) twice

1c10 (tt) twice

4E7

And fill (tt) twice

1 B 1 (tt) twice

1 H₂ (H) twice

2E8 (++) twice

1 F 5

Δ 1 D8 (++) once (t) once

 $v_{IH4}(t)$ once

A2 group

Δ 7G9 (+) once (+) once

8c2 (+) twice

Δ 843 (+) twice

Δ 8 8 8 8 (ttt) once (+) once (o) once

Δ 6C4 (TT) once (T) ~~once~~ twice

7B6 (+) twice (0) once


TITLE

PROJECT NO.

37

BOOK NO.

Work



B group do isotype assay, we got ^{all} IgM
so we select

1B3 1A8 (A) to do ascite fluid
2D4 1F3 (B)
3C7 2C5 (C)
2E8 2G5 (D)
4E7 1F11 (E)
1F5 1D8 (F)

SCIENTIFIC BINDERY PRODUCTIONS CHICAGO 60605 MADE IN USA

SIGNATURE

DISCLOSED TO AND UNDERSTOOD BY

DATE

work continued to Page

WITNESS

DATE

8/5/99

DATE

10-1-99

Flow Cytometry Analysis of mAbs Bound to Mouse Sperm Cells

(Four mAbs A, B, C and D show the binding of mouse sperm cells)

9/2

Cow

BAG (Ken)
FITC

2 Sep 99
1530-1645

HdN
488 (I22)/500nmW

No Threshold

60.5/60.0




Bovine Sperm #4

Att	CI	PI	Log	PMI	N.
30	C1	P2	Log	580V	PMI 1
ITC	C2	P3	Log	620V	3
ITC	C2	M-Log	550V		5


BAG-1999-09-02-000


Sample ID	Species	Extender	Ante
-000	Bovine	Extender	2nd only
-002	"	"	Myelin
-003	"	"	C
-004	"	"	D
-005	"	PBS	Ante
-006	"	"	2nd only
-007	"	"	Myelin
-008	"	"	C
-009	"	"	D

Sample ID	Species	Ante
-010	Mouse	Ante
-011	"	2nd only
-012	"	Myelin Tubulin
-013	"	Myelin
-014	"	A
-015	"	B
-016	"	C
-017	"	D




229 G2: R4 & R1






Region	Count	%	Mean
Total	50000	100.00	619.91, 204.17
R1	8714	17.43	2700.21, 895.86




Region	Count	%	Mean
Total	8744	100.00	156.37, 300.47
R4	6912	79.05	142.58, 283.17






Region	Count	%	Mean
Total	6912	100.00	875.93, 283.17
R2	6464	93.52	863.97, 83.17
R3	349	5.05	1063.07, 1468.16


361 G2: R4 & R1






Region	Count	%	Mean
Total	6912	100.00	283.17



409 G2: R4 & R1







Region
Total
Count
50000
R1
8680
%
100.00
17.32
Mean
619.08, 197.16
2737.25, 902.77


Region
Total
Count
8685
R4
6802
%
100.00
78.23
Mean
157.27, 278.34
142.89, 245.51

Region
Total
Count
6802
R2
6438
R3
286
%
100.00
94.65
4.20
Mean
870.77, 245.51
860.34, 85.49
1055.34, 1317.32






Region	Count	%	Mean
Total	50000	100.00	616.58, 195.81
R1	8966	17.93	2723.48, 879.04




Region	Count	%	Mean
Total	8994	100.00	156.57, 1082.71
R4	7083	78.75	142.66, 994.57




Region	Count	%	Mean
Total	7083	100.00	845.48, 994.57
R2	759	10.72	764.37, 104.30
R3	6211	87.69	852.70, 950.42


232 G2: R4 & R1




Region	Count	%	Mean
Total	7083	100.00	994.57



Region	Count	%	Mean
Total	50000	100.00	614.11, 202.03
R1	8893	17.79	2725.28, 886.85




Region	Count	%	Mean
Total	8915	100.00	155.73, 468.50
R4	7091	79.54	142.51, 407.76




Region	Count	%	Mean
Total	7091	100.00	844.39, 407.76
R2	3930	55.42	809.01, 114.17
R3	3062	43.18	881.24, 497.85


G2: R4 & R1




Region	Count	%	Mean
Total	7091	100.00	407.76



Region	Count	%	Mean
Total	50000	100.00	611.90, 201.63
R1	8939	17.88	2737.66, 905.07




Region	Count	%	Mean
Total	8970	100.00	157.07, 2822.53
R4	7007	78.12	142.94, 2687.92




Region	Count	%	Mean
Total	7007	100.00	879.12, 2687.92
R2	529	7.55	824.18, 82.87
R3	6083	86.81	881.79, 2474.10


178 G2: R4 & R1




Region	Count	%	Mean
Total	7007	100.00	2687.92



Region	Count	%	Mean
Total	50000	100.00	609.38, 197.20
R1	9020	18.04	2716.36, 880.21




Region	Count	%	Mean
Total	9050	100.00	155.80, 1212.35
R4	7213	79.70	142.79, 1156.87



Region	Count	%	Mean
Total	7213	100.00	867.66, 1156.87
R2	1636	22.68	790.21, 103.34
R3	5467	75.79	888.59, 1304.66

133 G2: R4 & R1




Region	Count	%	Mean
Total	7213	100.00	1156.87

Generation of Transgenic Mice from Two Different Linkers mAb C and mAb D

Transgenic Mice Generated from mAb D Linker

by Southern Blot Analyses



Date: November 17, 2000

